Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine

BACKGROUND: Previously published three-month placebo-controlled and one-year open-label clinical trial data have provided information on the efficacy and safety of erenumab. METHODS: Interim analysis was undertaken from an ongoing five-year open-label treatment phase after all patients completed thr...

Descripción completa

Detalles Bibliográficos
Autores principales: Ashina, Messoud, Goadsby, Peter J, Reuter, Uwe, Silberstein, Stephen, Dodick, David, Rippon, Gregory A, Klatt, Jan, Xue, Fei, Chia, Victoria, Zhang, Feng, Cheng, Sunfa, Mikol, Daniel D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6779015/
https://www.ncbi.nlm.nih.gov/pubmed/31146544
http://dx.doi.org/10.1177/0333102419854082

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6779015/
https://www.ncbi.nlm.nih.gov/pubmed/31146544
http://dx.doi.org/10.1177/0333102419854082

Ejemplares similares